As the prevalence of cardiometabolic risk factors, such as obesity, high blood pressure, diabetes, abnormal cholesterol levels, and hypercoagulability, continue to increase, as well as aging of the population, the incidence of heart failure (HF) will continue to rise, along with the unmet needs of patients. Recent studies have shown that only 40% of patients with HF receive evidence-based treatment recommended by guidelines; less than half of patients with HF take beta-blockers; and only a third take angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs). Additionally, only 7% of African Americans diagnosed with HF are receiving guideline recommended fixed-dose hydralazine and isosorbide dinitrate.
This symposium will focus on identifying the risk of HF in patients with cardiometabolic disease, provide an overview on the most recent focused update of the HF guidelines, identify the safety and efficacy of recently approved pharmacotherapies for HF, and implement coordination of care strategies to optimize patient outcomes. Expert faculty will also provide patient cases to provide participants with real world solutions to clinical challenges.